GLP1's Weekly Pills Pens and Progress 14

Posted on November 16, 2026 by Sally-Anne Turner

As we move into the last quarter of the year, our team at the Bodyline Clinic are looking forward to the potential of adding adolescent GLP-1 treatments to our care packages.

There is a lot to get through but watch this space! And it seems that when it comes to weight loss injections, there is more research being pushed into the role of weight loss medication in the realm of younger patients.

From more GLP-1 research being needed in teens, to Novo Nordisk and semaglutide in the media and psoriasis treatments with weight loss injections like tirzepatide, here, we break down all the new stuff happening in the world of GLP-1s.

So, welcome to GLP-1s Weekly Pills, Pens and Progress 14.

Adolescent GLP-1 Treatments: The Opportunity for Better Long-Term Health

The growing use of GLP-1 medications in adolescents living with obesity offers an important opportunity to improve weight-related health and long-term wellbeing.

A 2026 Cochrane review highlights that while these treatments can improve weight-related outcomes, more research is needed to understand their wider and longer-term benefits during adolescence.

Improved weight health has the potential to support metabolic health, physical wellbeing, confidence and quality of life, while reducing future health risks.

The next step is more comprehensive research exploring these benefits, including growth, development, psychological wellbeing and health outcomes into adulthood. Studies should also consider how GLP-1 treatments can complement lifestyle and nutritional support.

Ultimately, we need to look beyond BMI and understand the full health benefits effective weight management can bring to young people.

So, what should happen? Ideally, more studies into teenagers and GLP-1s that last at least one year. There also needs to be broader measurements for these treatments than just weight or BMI. Also, do these weight loss medications create more benefits for teens than lifestyle interventions?

Again, this highlights the need for more specialised assessment with GLP-1 medicines, rather than blanket prescribing guidelines.

Look at the original paper here: Cochrane – Weight-loss medicines in children and adolescents.

Zepbound and Psoriasis

Ever heard of psoriasis?

It is a skin condition that results in plaques or hardened skin building up. Typical treatments for it include steroid creams or even oral steroids such as prednisolone.

New research from JAMA Dermatology notes that when tirzepatide is mixed with psoriasis treatment ixekizumab, this may improve outcomes for adults who have both obesity and moderate-to-severe plaque psoriasis.

The phase 3b TOGETHER-PsO trial looked into obesity and psoriasis to see if they could find a way to treat both. With 274 participants, it found that:

  1. At 36 weeks, 27.1% of participants receiving combination treatment achieved both complete psoriasis skin clearance. There was also 10% weight loss in the combination group compared with 5.8% receiving ixekizumab alone.
  2. Complete skin clearance was also more prevalent in the combination group. It occurred in 40.6% of participants compared with 29.0% receiving ixekizumab alone.

Psoriasis is often linked to inflammation. In those who are diagnosed with obesity, there is also often chronic low levels of inflammation. So, treating both conditions at the same time is likely to improve clinical outcomes.

As is the case with these medications, this study does not state that tirzepatide can treat psoriasis. More research is needed to better establish the underlying mechanisms and any long-term benefits.

Check out the research paper here: Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial | Trials | JAMA Dermatology | JAMA Network

Semaglutide and Vision Loss

We have spoken at length about Novo Nordisk.

They are the manufacturers behind GLP-1 medications Ozempic and Wegovy. However, they are currently facing lawsuits in the US. Why? There are allegations that the core ingredient in both Wegovy and Ozempic has contributed to a rare eye condition that can lead to permanent vision loss.

The name of this condition? Non-arteritic anterior ischemic optic neuropathy (NAION). This happens when blood flow to the optic nerve becomes insufficient and can cause painless vision loss, usually confined to one eye.

The report notes patients developing vision impairments while taking semaglutide. This has, understandably, raised questions about these medications and the potential risks.

Even though these allegations have hit Novo Nordisk, as always, it does not establish that this medication is the direct cause of this occurring. In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) has already reviewed this safety concern.

It was noted in 2026 that NAION was a rare side effect of semaglutide, estimated to impact one in 10,000 users. Its assessment suggested approximately twice the relative risk among adults with type 2 diabetes, equivalent to roughly one additional case per 10,000 people treated annually.

You may be noting a trend. The majority of the findings and the research that we write about in GLP_1s Weekly highlight the need for those taking these medications to be aware of all side-effects and for there to be medical oversights through treatment.

See the original piece here: GLP-1s: Novo Nordisk and Eli Lilly face lawsuits over vision loss and eye damage | The BMJ

Speaking of more clinical intervention from medical teams, that is precisely what our team at the Bodyline Clinic offers. Whether you are looking for weight loss treatments like Wegovy, or appetite suppressants like phentermine UK, we can help you to hit your weight loss goals safely with the help of our clinical team.

Sound good? Contact our team today!

About The Author

Sally-Anne Turner

I am founder and Managing Director of Bodyline, with over two decades of experience in the healthcare and wellness industries. I combine a deep understanding of medical wellness with a passion for science-backed health solutions and future-focused care. I have a specialist interest in developing gold standard clinical services for medical weight loss, including the latest GLP-1 medications, hormone health, and low-dose naltrexone (LDN) treatments.

Related Treatment News